Healius Limited (AU:HLS)
ASX:HLS
Want to see AU:HLS full AI Analyst Report?
Top Page
Healius Limited
(Sydney:HLS)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.37
▼(-31.85% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by weak financial performance (revenue decline, losses, and high leverage) and a clear bearish technical setup (price below all major moving averages with negative MACD). Valuation is also pressured by negative earnings (negative P/E) and no dividend yield data to offset risk, partially tempered by positive operating cash flow.
Positive Factors
Operating cash generation
Healius's positive operating cash flow provides durable liquidity to fund day-to-day lab operations and working capital. Over a 2-6 month horizon this reduces immediate refinancing pressure, supports continuity of diagnostic services and gives management time to execute margin recovery measures.
Negative Factors
Revenue decline and negative margins
A 13.8% revenue decline coupled with an -11.2% net margin signals persistent demand or pricing pressure. Continued top-line contraction weakens scale economics, increases per-unit fixed costs and constrains the pathway to sustained profitability over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Operating cash generation
Healius's positive operating cash flow provides durable liquidity to fund day-to-day lab operations and working capital. Over a 2-6 month horizon this reduces immediate refinancing pressure, supports continuity of diagnostic services and gives management time to execute margin recovery measures.
Read all positive factors
Healius Limited (HLS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$250.52M
Dividend YieldN/A
Average Volume (3M)2.94M
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue Growth-12.15%
EPS Growth-2285.99%
CountryAU
Employees4,329
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.75
Shares Outstanding726,155,800
10 Day Avg. Volume3,249,015
30 Day Avg. Volume2,941,962
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.26
Price to Sales (P/S)0.11
P/FCF Ratio0.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.44Price Target Upside-18.52% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering6
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$1.38B
Healius Limited Business Overview & Revenue Model
Company Description
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical la...
How the Company Makes Money
Healius makes money primarily by providing fee-for-service diagnostic healthcare to patients referred by doctors and other clinicians. The core revenue streams are (1) pathology: the company collects patient samples (e.g., blood and other specimen...
Healius Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37B | 1.34B | 1.75B | 1.71B | 2.29B | 1.90B |
| Gross Profit | 331.90M | 398.60M | 1.52B | 341.70M | 779.20M | 526.50M |
| EBITDA | 206.80M | 31.20M | -298.10M | -57.80M | 734.80M | 470.40M |
| Net Income | -168.80M | -151.20M | -645.80M | -367.80M | 307.90M | 43.70M |
Balance Sheet | ||||||
| Total Assets | 1.77B | 1.78B | 2.98B | 3.65B | 4.14B | 3.78B |
| Cash, Cash Equivalents and Short-Term Investments | 51.60M | 57.20M | 60.10M | 115.30M | 81.30M | 70.10M |
| Total Debt | 1.66B | 911.80M | 1.60B | 1.77B | 1.78B | 1.44B |
| Total Liabilities | 1.22B | 1.19B | 1.94B | 2.15B | 2.22B | 1.92B |
| Stockholders Equity | 557.10M | 587.90M | 1.04B | 1.51B | 1.92B | 1.86B |
Cash Flow | ||||||
| Free Cash Flow | 124.30M | 231.70M | 173.80M | 230.30M | 480.30M | 432.00M |
| Operating Cash Flow | 174.70M | 285.70M | 266.80M | 306.40M | 573.80M | 493.30M |
| Investing Cash Flow | 734.50M | 730.00M | -63.00M | 67.30M | -401.70M | 386.90M |
| Financing Cash Flow | -973.90M | -1.02B | -259.00M | -339.70M | -163.50M | -984.70M |
Healius Limited Technical Analysis
Negative
0.54
Price Trends
0.53
Negative
0.70
Negative
0.77
Negative
Market Momentum
-0.05
Positive
26.54
Positive
7.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HLS, the sentiment is Negative. The current price of 0.54 is above the 20-day moving average (MA) of 0.48, above the 50-day MA of 0.53, and below the 200-day MA of 0.77, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 26.54 is Positive, neither overbought nor oversold. The STOCH value of 7.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HLS.
Healius Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$9.26B | 10.64 | 6.39% | 4.69% | 13.14% | -2.73% | |
67 Neutral | AU$284.43M | 10.00 | 6.06% | 6.22% | -0.03% | ― | |
59 Neutral | AU$355.64M | 23.92 | 16.35% | 4.60% | 1.12% | -12.02% | |
55 Neutral | AU$786.72M | 26.42 | 2.05% | 2.65% | 56.28% | 55.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$250.52M | -5.40 | -29.48% | ― | -12.15% | -2285.99% | |
46 Neutral | AU$115.48M | -7.39 | -164.12% | ― | -14.85% | -41.04% |
* Healthcare Sector Average
AU:HLS
Healius Limited
0.36
-0.71
-66.67%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.12
0.09
300.00%
AU:SHL
Sonic Healthcare Limited
18.39
-6.94
-27.41%
AU:IDX
Integral Diagnostics Ltd.
2.07
-0.33
-13.86%
AU:ACL
Australian Clinical Labs Ltd
1.84
-1.11
-37.78%
AU:MVF
Monash IVF Group Ltd
0.72
-0.12
-14.27%
Healius Limited Corporate Events
Healius flags asset sale and funding squeeze as wage pressures mount
May 12, 2026
Healius has issued a trading update for FY 2026, forecasting group underlying EBITDA of $259 million to $264 million and underlying EBIT of $30 million to $35 million, as modest revenue growth and cost controls support profitability. Pathology rev...
Healius Updates Market on Director Katherine Ostin’s Vesting of Share Rights
Apr 23, 2026
Healius Limited has disclosed a change in the interests of non-executive director Katherine Ostin, reflecting the vesting of share rights into fully paid ordinary shares under the company’s non-executive director (NED) share plan. The transa...
Healius Seeks ASX Quotation for New Ordinary Shares
Apr 21, 2026
Healius Limited has applied to the ASX for quotation of 22,978 new ordinary fully paid shares, with an issue date of 23 April 2026. The additional securities arise from the exercise or conversion of existing options or other convertible instrument...
Dimensional Fund Advisors Exits Substantial Holder Status in Healius
Apr 15, 2026
Dimensional Fund Advisors and its related entities have notified Healius that they have ceased to be a substantial holder in the company as of 13 April 2026. The change reflects a reduction in Dimensional’s relevant voting interest below the...
Macquarie Group Ceases to Be Substantial Holder in Healius
Apr 13, 2026
Macquarie Group Limited and its controlled entities have lodged a notice stating they have ceased to be substantial holders in Healius Limited. The filing, signed by Macquarie’s company secretary on 13 April 2026, indicates changes in releva...
Macquarie Group Ceases to Be Substantial Holder in Healius
Apr 7, 2026
Macquarie Group Limited and a wide range of its controlled entities have lodged a notice that they have ceased to be substantial holders in Healius Limited. The filing, signed by Macquarie’s company secretary, formalises the change in Macqua...
Healius Details Shareholdings as Director John Mattick Departs Board
Mar 31, 2026
Healius Limited has announced that Professor John Mattick ceased to be a director of the company effective 31 March 2026, lodging a final notice of his relevant interests in the company’s securities. The filing discloses that Mattick directl...
Healius Director Katherine Ostin Increases Indirect Shareholding
Mar 13, 2026
Healius Limited has disclosed a change in director Katherine Ostin’s interests in the company’s securities, following an on‑market purchase of additional fully paid ordinary shares. Ostin’s indirect holding, through Nitso P...
Healius Director Steven Rubic Increases Shareholding via On-Market Purchase
Mar 12, 2026
Healius Limited has disclosed a change in the shareholding of director Steven Rubic, who increased his direct holding in the company through on-market trades. Rubic acquired 130,000 fully paid ordinary shares at an average price of $0.595 per shar...
Healius director Katherine Ostin increases shareholding via on-market trades
Mar 10, 2026
Healius has disclosed a change in the interests of non-executive director Katherine Ostin, following on-market purchases of additional fully paid ordinary shares in the company. Ostin acquired 16,264 shares at an average price of $0.6148 per share...
Healius Director Katherine Ostin Lifts Indirect Shareholding in On‑Market Trades
Mar 5, 2026
Healius Limited has disclosed a change in the securities held by non‑executive director Katherine Ostin, detailing updated direct and indirect interests in the company’s fully paid ordinary shares. The filing notes that Ostin’s i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.